Previous 10 | Next 10 |
aTyr Pharma, Inc. (LIFE) Q2 2020 Earnings Conference Call August 13, 2020 05:00 p.m. ET Company Representatives Sanjay Shukla - President, Chief Executive Officer Jill Broadfoot - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Hartaj Singh...
aTyr Pharma (NASDAQ: LIFE ) : Q2 GAAP EPS of -$0.69 beats by $0.04 . More news on: aTyr Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update. “...
aTyr Pharma's ( LIFE +0.8% ) announces that Japan's Pharmaceutical and Medical Devices Agency (PMDA) has signed off on collaboration partner Kyorin Pharmaceutical's ( OTC:KYRNF ) trial application for Phase 1 study of aTyr’s lead therapeutic cand...
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a who...
SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and prov...
Vancouver, British Columbia--(Newsfile Corp. - June 26, 2020) - World High Life (OTCQB: WRHLF) (AQSE: LIFE), an investment company established to take advantage of the huge opportunities available in the UK and European legal cannabis space, has appointed Ross Westbrook as Advisor for North Am...
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bioth...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory responses. SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc....
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...